INS and metabolic disease: Researchers have reported that drug-naïve patients or patients from the pre-medication era have metabolic disorders such as a higher body mass index (BMI), waist circumference, and low-density lipoprotein (LDL) levels; hyperinsulinemia; and abnormalities in insulin secretion (Harris et al., 2013; Freyberg et al., 2017).